A Phase 1 interventional study of Comparator: pregabalin and Comparator: Placebo (unspecified) in Neuralgia, Postherpetic, Diabetic Neuropathy and Painful Small-Fiber Neuropathy, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing pregabalin in Neuralgia, Postherpetic — 3 open to participants now, 3 under way, 1 of them phase 3. Pregabalin · Neuralgia, Postherpetic.
Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, this one is the 11th largest by enrollment, is one of 3 that started in 2007, is one of 2 in phase 1, and was the 6th registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →3 of the 15 studies testing pregabalin in Neuralgia, Postherpetic are open now, in 3 countries. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
Zhejiang Chinese Medical University · Sites in China
Ages 50–80
Neurodawn Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 126 across the 15 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 9 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 6 studies filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
1 of the studies testing pregabalin in Neuralgia, Postherpetic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
Drug: Comparator: pregabalin
Patients in Group B will be treated with placebo.
Drug: Comparator: Placebo (unspecified)
pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
Daily Evening Patient Reported Pain Intensity Scores
Change from mean of last 3 days of maintenance period to last 3 days of double-blind period; Pain Intensity was rated on a 0-10 numeric rating scale (NRS: 0=no pain, 10=worst pain you can imagine)
Time frame: Baseline and 6 Weeks
'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study
Time to treatment failure (3 day mean of average 24 hour pain intensity ≥ 4 with at least a 30% increase relative to the last 3 days prior to randomization)
Time frame: 6 Weeks
Last Patient Entered: 06-Dec-07 Last Patient Last Visit: 11-Sep-08 # Sites: 20 sites randomized at least 1 patient. 21 sites screened at least 1 patient
| Milestone | Pregabalin | Placebo |
|---|---|---|
| Started | 53 | 51 |
| Completed | 51 | 45 |
| Not completed | 2 | 6 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 4 |
Change from mean of last 3 days of maintenance period to last 3 days of double-blind period; Pain Intensity was rated on a 0-10 numeric rating scale (NRS: 0=no pain, 10=worst pain you can imagine)
| Units on a Scale | Pregabalin | Placebo |
|---|---|---|
| Daily Evening Patient Reported Pain Intensity Scores | 0.14 (-2.00 to 4.33) | 1.57 (-1.83 to 8.00) |
Time to treatment failure (3 day mean of average 24 hour pain intensity ≥ 4 with at least a 30% increase relative to the last 3 days prior to randomization)
| Days | Pregabalin | Placebo |
|---|---|---|
| 'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study | 15.54 (3 to 21) | 7.87 (3 to 21) |
Collected over The reported AEs were collected after patients were randomized to the double-blind withdrawal period of the study. AEs that were collected prior to randomization are not reported in this document.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 0/51 (0%) | 37/51 (72.5%) |
| Placebo | — | 1/53 (1.9%) | 36/53 (67.9%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| ArrhythmiaCardiac disorders | 0/51 | 1/53 |
| Event | Pregabalin | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 10/51 | 11/53 |
| SomnolenceNervous system disorders | 8/51 | 7/53 |
| ConstipationGastrointestinal disorders | 6/51 | 2/53 |
| Dry MouthGastrointestinal disorders | 6/51 | 2/53 |
| Oedema PeripheralGeneral disorders | 5/51 | 3/53 |
| FatigueGeneral disorders | 4/51 | 4/53 |
| Vision BlurredEye disorders | 3/51 | 4/53 |
| VertigoEar and labyrinth disorders | 3/51 | 0/53 |
| NauseaGastrointestinal disorders | 3/51 | 1/53 |
| Weight IncreasedInvestigations | 3/51 | 2/53 |
| Age, Continuous(years) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Mean | 61.7 ± 10.8 | 59.3 ± 11.0 | 60.5 ± 10.9 |
| Sex: Female, Male(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Female | 8 | 14 | 22 |
| Male | 22 | 18 | 40 |
| Body Mass Index(kilograms/meter^2) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Mean | 32.6 (20.9 to 49.3) | 31.3 (18.5 to 49.5) | 31.9 (18.5 to 49.5) |
No study locations are listed for this record.
The record gives a start of Dec 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin